Viridian reports $24.7M in Lumvoa sales in launch quarter, BLA for elegrobart on track for Q1 2027

Viridian Therapeutics reported third-quarter 2026 financial results and business updates on November 4, 2026. Lumvoa (veligrotug-vvze) generated $24.7 million in net product revenue in its first full quarter of launch, with more than 100 patients on therapy by September 30, 2026.¹ The company also said CMS has assigned Lumvoa a permanent J-code, J3242, effective January 1, 2027.¹

On the pipeline side, Viridian said it remains on track to submit a Biologics License Application to the FDA for elegrobart in thyroid eye disease in the first quarter of 2027.¹ If approved, the company plans to launch elegrobart as an autoinjector for at-home subcutaneous dosing every four or eight weeks.¹

For its TSHR program, Viridian said the VRDN-292 IND remains on track to support initiation of a phase 1 clinical trial in patients with Graves' disease in the fourth quarter of 2026.¹ The company described VRDN-292 as "a potential best-in-class, half-life extended, monoclonal antibody" aimed at the thyroid-stimulating hormone receptor, according to the release.

In the FcRn portfolio, Viridian reported that in a phase 1 healthy volunteer trial, VRDN-006 reduced IgG consistent with the FcRn inhibitor class while sparing albumin and LDL, and was generally well tolerated.¹ For VRDN-008, the company cited a non-human primate study in which a single high dose produced a longer half-life and more sustained IgG reduction compared with efgartigimod. Viridian said it expects to disclose VRDN-008 phase 1 healthy volunteer data and outline development plans for the FcRn portfolio in the fourth quarter of 2026.¹

On financing, Viridian reported $955.2 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which along with anticipated commercial revenue from Lumvoa and elegrobart, if approved, the company said is expected to fund its business plans through profitability.¹